News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
XRP Price Prediction: $1.35 Support Tested As Network Activity Jumps 40%
CoinEdition·2026/02/25 10:39
Annual inflation in the euro area drops to 1.7%
101 finance·2026/02/25 10:03
WTI falls under $66.00 as rising US crude inventories heighten worries about excess supply
101 finance·2026/02/25 09:42
XMTP and Mask Network Partner to Standardize Secure Messaging Across Lens, Orb, and Firefly
BlockchainReporter·2026/02/25 09:30
Are AI Agent Paywalls Coming? Software Companies Consider How to Address AI Risks
新浪财经·2026/02/25 09:23
Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027
Finviz·2026/02/25 09:15
Bitcoin’s Next Big Move? Gamma Data Highlights $60K Risk, $90K Resistance
CoinEdition·2026/02/25 09:06
Bitcoin’s weekly RSI hits an all-time low – Is a bear trap brewing?
AMBCrypto·2026/02/25 09:03
Flash
21:05
According to industry sources, there are rumors that Qualcomm is about to complete its acquisition of the AI chip startup Modular.The current global competition in the AI chip sector is becoming increasingly fierce. If Qualcomm successfully completes its acquisition of Modular, it is expected to leverage this startup's technological expertise to further strengthen its own technical reserves and market competitiveness in the AI chip space. This move could also have a certain impact on future technological iterations and the market landscape of the AI chip industry.
21:02
According to data released by the Bank of Korea, the median consumer inflation expectation in South Korea for the next 12 months in June is 2.8%, which is unchanged from the median inflation expectation in May.This data reflects that South Korean consumers’ short-term expectations for price trends remain relatively stable, with no significant fluctuations observed.
20:57
Pfizer shares fell 1% in after-hours tradingPreviously, the company announced the Phase III clinical trial results for its drug Sigvotatug Vedotin, which showed that the drug failed to significantly improve overall survival in patients. This outcome delivered a setback to Pfizer’s highly anticipated oncology pipeline. The market reacted promptly to this news, testing investor confidence. The stock price volatility reflected the market’s heightened sensitivity to R&D progress and a reassessment of future revenue potential. Despite this setback, Pfizer’s overall R&D pipeline remains extensive. The company stated it will continue to advance other ongoing projects. However, the failure of this key study undoubtedly adds uncertainty to the competitive landscape in the related field and underscores the inherent high risks of new drug development.
News